Evogene (EVGN) vs Imunon (IMNN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Evogene is the larger company by market cap ($6.3 million vs $6.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVGN | IMNN |
|---|---|---|
| Share price | $0.3985 | $1.07 |
| Market cap | $6.30M | $6.00M |
| 1-day change | -2.95% | -4.46% |
| EPS (TTM) | $-1.55 | $-3.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.49 | $5.39 |
| 52-week low | $0.35 | $1.03 |
| Distance from 52-week high | -73.26% | -80.15% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +439.52% | +1488.79% |
| Average volume | 2.02M | 155.30K |
| Shares outstanding | 15.80M | 5.61M |
| Employees | 38 | 20 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Evogene
EVGN stock →Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications.
Healthcare · Biotechnology · 38 employees
About Imunon
IMNN stock →Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma.
Healthcare · Biotechnology · 20 employees
EVGN vs IMNN FAQ
Which is bigger, Evogene or Imunon?
Evogene (EVGN) is larger, with a market capitalization of $6.30M compared with $6.00M for Imunon (IMNN).
Are Evogene and Imunon in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.